ReviewFrontiers in oncology2022
Cancer diagnosis in areas of conflict.
Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Validation of the Arabic Version of Patient Health Questionnaire-9 in Omani and Yemeni Patients With Chronic Physical Diseases.International journal of methods in psychiatric research · 2026Article
- Cancer Care in the Gaza Strip Before and During War: Patient Experiences of Treatment Disruption, Unmet Support Needs, and Interdisciplinary Implications for Medicine, Nursing, and Social Work.Psycho-oncology · 2026Article
- Cancer care in conflict-affected regions: a scoping review of service delivery challenges, healthcare system adaptations, and policy implications.Conflict and health · 2026Review
- Liver disease care amid wars and conflicts.Nature reviews. Gastroenterology & hepatology · 2026Article
- Challenges and strategies for delivering effective breast cancer care in conflict zones.Communications medicine · 2026Review
- Theranostics and nuclear medicine practice in Asia-Pacific: an IAEA regional study.European journal of nuclear medicine and molecular imaging · 2026Review
- Occupation and oncology: cancer care in Palestine.Frontiers in oncology · 2026Review
- Rethinking cancer care in conflict settings: lessons from Ukraine.BMJ oncology · 2026Article
- Nuclear Medicine in IRAQ: From a Pioneering Past to Future Progress.Journal of multidisciplinary healthcare · 2026Review
- Analysis of Anatomical pathology laboratory capabilities in eastern Democratic Republic of Congo.PLOS global public health · 2026Article
- Health conditions of older adults in complex humanitarian settings in low- and middle-income countries: a retrospective analysis of 2019-2025 data from Médecins Sans Frontières-supported inpatient departments.BMJ global health · 2025Article
- Current Status of Theranostics in West Asia: A Country-based Surveillance Study.Nuclear medicine and molecular imaging · 2025Review
- Theranostics and molecular imaging training in the arab world: present and prospects.European journal of nuclear medicine and molecular imaging · 2024Article
- Trends in nuclear medicine and the radiopharmaceutical sciences in oncology: workforce challenges and training in the age of theranostics.The Lancet. Oncology · 2024Review
- An Overview of Appropriate Medical Practice and Preparedness in Radiation Emergency Response.Cureus · 2024Review
- Understanding referral of patients with cancer in rural Ethiopia: a qualitative study.BMC cancer · 2024Article
- Systemic Barriers to Optimal Cancer Care in Resource-Limited Countries: Jordanian Healthcare as an Example.Cancers · 2024Review
- Lung Cancer Diagnoses and Outcomes During the Syrian War, 2011-2018.JAMA network open · 2024Article
- HealthCare Access Barrier (HCAB) framework for the barriers to cancer care during conflicts: perspective from Iraq.BMJ oncology · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To date, many Arab countries within the Middle East are facing political, financial, and social instability from war and conflicts. These conflicts have led to severe resources shortages and sometimes complete breakdowns in cancer care and diagnosis. Cancer diagnosis at early stages is the most vital step in achieving optimal cancer care and outcomes. Shortages in cancer diagnostic services have meant that many people within areas of conflict are ultimately deprived of these services in their own countries. Therefore, many of these cancer sufferers must bear travel expenses to neighboring countries in order to seek these services. A lack of prevention, screening, and diagnostic services for this population is known to deepen the cancer care deficit within these areas. Additionally, the financial burden of traveling abroad alongside the need to secure childcare and time off work can be overwhelming. As a result, patients within areas of conflict are frequently diagnosed at later stages and are less likely to receive optimal management plans. Though conflict-affected regions encounter many similar challenges in delivering quality cancer care, pronounced region-specific differences do exist. Therefore, it is important to build a roadmap that can provide tailored solutions to deficits in instruments, manpower, and facilities for each and every region involved. Keeping in mind the importance of collaboration and coordination on national and international levels to address the ground disparity in cancer diagnostic services, the main objective of this review article is to examine the significant problems, shortages, and difficulties in providing cancer diagnosis with a focus on imaging to conflict-affected populations in the Middle East (mainly Iraq, Syria, Yemen, and Sudan). Finally, we discuss how access to cancer diagnostic imaging services has been impacted by these conflicts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.